Alicia Batts, Dylan Carson and Anna Behrmann Author Law360 Article on Possible Increased Antitrust Scrutiny of Pharma Companies by Biden Administration

Business litigation partners Alicia Batts and Dylan Carson and associate Anna Behrmann coauthored an article for Law360 that highlights recent developments from the Federal Trade Commission (FTC), which suggest that competition enforcement in the pharmaceutical sector is likely to increase in the next four years under the Biden administration.

The article discusses the FTC’s announcement of the formation of an international working group to study the competitive effects of pharmaceutical mergers and to coordinate prospective merger analysis. The authors also provide examples of how the FTC has taken a more aggressive stance in its current pharmaceutical merger reviews and conduct investigations – litigating its first vertical merger in decades and filing another case alleging an anticompetitive reverse payment agreement to delay the entry of a generic competitor.

The full article is available for Law360 subscribers.